AU2001291019A1 - Method of modulating neovascularization - Google Patents

Method of modulating neovascularization

Info

Publication number
AU2001291019A1
AU2001291019A1 AU2001291019A AU9101901A AU2001291019A1 AU 2001291019 A1 AU2001291019 A1 AU 2001291019A1 AU 2001291019 A AU2001291019 A AU 2001291019A AU 9101901 A AU9101901 A AU 9101901A AU 2001291019 A1 AU2001291019 A1 AU 2001291019A1
Authority
AU
Australia
Prior art keywords
modulating neovascularization
neovascularization
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001291019A
Inventor
Imre Kovesdi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genvec Inc
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of AU2001291019A1 publication Critical patent/AU2001291019A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AU2001291019A 2000-09-15 2001-09-14 Method of modulating neovascularization Abandoned AU2001291019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23300100P 2000-09-15 2000-09-15
US60233001 2000-09-15
PCT/US2001/028954 WO2002022176A1 (en) 2000-09-15 2001-09-14 Method of modulating neovascularization

Publications (1)

Publication Number Publication Date
AU2001291019A1 true AU2001291019A1 (en) 2002-03-26

Family

ID=22875461

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001291019A Abandoned AU2001291019A1 (en) 2000-09-15 2001-09-14 Method of modulating neovascularization

Country Status (3)

Country Link
US (1) US6753321B2 (en)
AU (1) AU2001291019A1 (en)
WO (1) WO2002022176A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154324A0 (en) * 2000-08-08 2003-09-17 Mgvs Ltd Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
WO2002081634A2 (en) * 2001-04-05 2002-10-17 The Johns Hopkins University Imaging nucleic acid delivery
WO2002088173A2 (en) * 2001-04-30 2002-11-07 Cell Genesys, Inc. Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins
US20030148952A1 (en) * 2001-10-18 2003-08-07 Crombleholme Timothy M. Methods and materials for the recruitment of endothelial cells
JP2005320251A (en) * 2002-05-10 2005-11-17 Ajinomoto Co Inc Arterialization agent and antiarterialization agent
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
CA2511315A1 (en) * 2002-12-31 2004-07-22 The Johns Hopkins University Wound healing method and kits
WO2005014022A1 (en) * 2003-07-16 2005-02-17 Develogen Aktiengesellschaft Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US7951532B2 (en) 2003-11-12 2011-05-31 Children's Hospital Medical Center Method of screening a midkine modulating agent
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US7422741B2 (en) 2004-03-05 2008-09-09 Vegenics Limited VEGFR-3 fusion proteins
WO2008028888A2 (en) * 2006-09-05 2008-03-13 Vib Vzw Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting
EP2125895B1 (en) * 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
US20080318241A1 (en) * 2007-06-18 2008-12-25 The Regents Of The University Of Michigan Methods and Systems for Detecting Antiangiogenesis
US8722638B2 (en) * 2008-06-20 2014-05-13 Children's Medical Center Corporation Methods for the modulation of angiogenesis
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
EP2550001B1 (en) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
EP3560503B1 (en) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
RU2737487C1 (en) * 2019-11-06 2020-12-01 Общество С Ограниченной Ответственностью "Генная И Клеточная Терапия" (Ооо "Генная И Клеточная Терапия") Genetic engineering structure for angiogenesis stimulation
CN114404601B (en) * 2022-03-31 2022-06-07 首都医科大学附属北京朝阳医院 Application of MDK inhibitor in preparing medicine for inhibiting tumor metastasis caused by interferon-gamma treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800579B1 (en) 1994-12-30 2002-07-24 Chiron Corporation Combination gene delivery vehicles
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
WO1997041844A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
EP1342477A1 (en) * 1996-07-16 2003-09-10 Archibald James Mixson, M.D. Cationic vehicle: dna complexes and their use in gene therapy
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
AU2493699A (en) 1998-02-04 1999-08-23 Zymogenetics Inc. Angiopoietin homolog zapo3, dna encoding it, and method of making it
AU767880B2 (en) 1998-03-16 2003-11-27 Introgen Therapeutics, Inc. Multigene vectors
US6673341B2 (en) 1998-07-06 2004-01-06 Beth Israel Deaconness Medical Center Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis
DK1093380T3 (en) 1998-07-09 2003-01-27 Applied Research Systems Component B as an angiogenic agent in combination with human growth factors
JP2002520020A (en) 1998-07-11 2002-07-09 グラクソ グループ リミテッド Use of NAB1 and NAB2 as drugs
EP1016726A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
EP1016727A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis.
US20030191055A1 (en) 1999-01-15 2003-10-09 Epstein Stephen E. Inhibiting development of microvessels withins coronary or peripheral vessel walls for restenosis/atherosclerosis prevention or therapy
CA2361535A1 (en) 1999-03-02 2000-09-08 Amway Corporation Method for marketing and selling that may contain a membership buying opportunity
ES2199804T3 (en) 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. MODULATION OF VASCULAR PERMEABILITY THROUGH TIE2 RECEIVER ACTIVATORS.
WO2002002148A2 (en) 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use

Also Published As

Publication number Publication date
WO2002022176A1 (en) 2002-03-21
US20030053989A1 (en) 2003-03-20
US6753321B2 (en) 2004-06-22

Similar Documents

Publication Publication Date Title
AU2001291019A1 (en) Method of modulating neovascularization
AU2001276934A1 (en) Methods of modulating fibrosis
AU3867400A (en) Methods of using bioelastomers
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU3803600A (en) Method of securing communication
AU2003234613A1 (en) Method of modulating angiogenesis
AU2001292864A1 (en) Methods and compositions for modulating angiogenesis
AU2002306918A1 (en) Methods of modulating angiogenesis
AU2001286983A1 (en) Method of treatment
AU2001247600A1 (en) Methods of modulating hair growth
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU2002366788A1 (en) Antisense modulation of ship-1 expression
AU2001244562A1 (en) Neovascularization inhibitors
AU2002318139A1 (en) Antisense modulation of src-c expression
AU2002357102A1 (en) Antisense modulation of cd36l1 expression
AU2001280588A1 (en) Methods of modulating angiogenesis
AU2001271426A1 (en) Modulation of apoptosis
AUPQ904100A0 (en) Method of encryption
AU2728901A (en) Method of making hydrofluorocarbons
AU2001262177A1 (en) Method of treatment
AU2002243429A1 (en) Antisense modulation of tnfr1 expression
AU2002347809A1 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
AU2002222927A1 (en) Method of making hydrofluorocarbons
AU2001288238A1 (en) Methods of modulating activity of dxr